https://www.novocure.com/ daily 1.0 https://www.novocure.com/novocure-announces-supply-agreement 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-appointment-gabriel-leung-its-board-directors 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-data-presentations-upcoming-sno-conference 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/updated-survival-data-phase-iii-trial-recurrent-glioblastoma-tumors-presented-sno 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-adds-three-senior-oncology-executives-management-team 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-appointment-chief-financial-officer 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/nccn-guidelinesr-recommend-novottftm-therapy-standard-treatment-option-cns-cancers 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-launch-recurrent-glioblastoma-product-website 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocures-pivotal-phase-3-trial-published-european-journal-cancer 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-eight-additional-centers-excellence 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/asco-2012-presentations 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/galien-foundation-selects-novottftm-100a-system-finalist-prix-galien-usa-award 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/sno-2012 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-appoints-four-new-independent-members-its-board-directors 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-first-patient-advanced-pancreatic-adenocarcinoma-study 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/brain-cancer-awareness-month-campaign 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/ef-14-registration-study-opens-enrollment-korea-patients-newly-diagnosed-gbm 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/2013-asco-press-release 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novottf-therapy-compassionate-use-japan 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/publication-phase-ii-lung-cancer-data 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/galien-foundation-selects-novottftm-therapy-finalist-2013-prix-galien-usa-award 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-fda-approval-novotaltm-transducer-array-layout-system 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-15-abstracts-be-presented-sno-2014 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-first-patient-brain-metastases-trial 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/launch-inovitrotm-laboratory-research-system 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/cms-establishes-hcpcs-codes-novottf-therapy 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/publication-preclinical-data-pancreatic-cancer 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/first-commercial-license-novotaltm-system 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-present-two-abstracts-aacr 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-sponsors-2014-brain-cancer-awareness-month 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-publication-new-survival-data-recurrent-gbm 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-additional-data-presented-commercial-registry 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-commercial-launch-novottftm-therapy-europe-and-israel 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-submission-pre-marketing-approval-application-japan-novottf-100a-system-treat 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novottftm-100a-system-granted-high-unmet-medical-need-designation-japanese-ministry-health-and 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocuretm-announces-recurrent-glioblastoma-patient-registry-dataset-pride-be-presented-esmo-and 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-publication-novottf-therapy-supplement-seminars-oncology-including-analyses-its 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-enrolls-first-patient-pilot-study-tumor-treating-fields-together-paclitaxel-treatment 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-optune-new-name-novottf-100a-system 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-presentation-new-data-19th-annual-society-neuro-oncology-meeting 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-ef-14-phase-iii-clinical-trial-tumor-treating-fields-patients-newly-diagnosed 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/interim-analysis-novocures-phase-iii-trial-newly-diagnosed-glioblastoma-be-presented-japan-society 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-fda-approval-ide-supplement-allowing-all-control-patients-its-phase-iii-trial 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-present-33rd-annual-jp-morgan-healthcare-conference 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-optune-now-available-more-150-leading-cancer-centers-across-united-states 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-100-million-term-loan-agreement-pharmakon-advisors 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-completion-enrollment-its-panova-trial-tumor-treating-fields-plus-gemcitabine 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-enrolls-first-patient-its-phase-ii-stellar-trial-tumor-treating-fields-together-pemetrexed 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-japanese-approval-optune-novottf-100a-system-treatment-recurrent-glioblastoma 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/intersect-ent-appoints-kieran-gallahue-and-tony-vernon-board-directors 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/new-preclinical-data-tumor-treating-fields-be-presented-american-association-cancer-research-annual 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-kicks-brain-tumor-awareness-month-new-activities-address-challenges-glioblastoma-community 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/fda-grants-priority-review-status-novocures-pma-supplement-application-optune-newly-diagnosed 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/nccn-guidelines-recommend-tumor-treating-fields-standard-treatment-option-recurrent-glioblastoma 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-present-new-clinical-and-preclinical-data-tumor-treating-fields-american-society-clinical 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-commercial-launch-optune-novottf-100a-system-japan 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-hosts-first-glioblastoma-focused-hackathon-develop-new-support-tools-gbm-brain-cancer 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-first-analysis-full-700-patient-dataset-successful-newly-diagnosed-gbm-phase-iii 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-launches-clinical-trial-website-wwwnovocuretrialscom 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-selected-technology-pioneer-world-economic-forum 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/data-tumor-treating-fields-be-presented-37th-annual-conference-ieee-engineering-medicine-and 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-present-clinical-trial-designs-and-preclinical-data-tumor-treating-fields-16th-world 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-optune-now-available-more-200-leading-cancer-centers-across-united-states 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-present-latest-data-ef-14-clinical-trial-newly-diagnosed-gbm-15th-interim-meeting-world 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-limited-announces-launch-initial-public-offering 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-limited-announces-launch-initial-public-offering-0 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-ce-mark-and-first-patient-use-second-generation-optune-system 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-limited-announces-closing-initial-public-offering 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/adding-multimedia-fda-approves-optune-combination-temozolomide-treatment-newly-diagnosed 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2015-financial-results-monday-october-26 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-offer-demand-optune-certification-training-radiation-oncology-community-astro-2015 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-limited-announces-closing-partial-exercise-ipo-over-allotment-option 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2015-operating-and-financial-results 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-webcast-discuss-new-ef-14-clinical-trial-analyses-and-tumor-treating-fields 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-announces-18-presentations-tumor-treating-fields-sno-2015-including-new-analyses-ef-14 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/new-phase-3-data-show-optune-combination-second-line-chemotherapy-superior-second-line-chemotherapy 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/preliminary-phase-2-data-demonstrate-tumor-treating-fields-safe-patients-brain-metastases 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/retrospective-analysis-shows-optune-safe-glioblastoma-patients-implanted-non-programmable-shunts 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/new-data-tumor-treating-fields-anti-mitotic-mechanism-action-published-scientific-reports 2025-02-20T12:08:56+01:00 0.5 https://www.novocure.com/novocure-hold-webcast-discuss-jama-publication-ef-14-phase-3-clinical-trial-data 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/journal-american-medical-association-jama-publishes-pivotal-phase-3-data-optune-plus-temozolomide 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-participate-34th-annual-jp-morgan-healthcare-conference 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-files-premarket-approval-supplement-application-fda-second-generation-optune-system 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-submits-pma-partial-amendment-application-japanese-pharmaceuticals-and-medical-devices 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-announces-preliminary-2015-operating-statistics 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-presents-phase-2-panova-results-asco-gi-suggesting-tumor-treating-fields-therapy-plus 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-report-fourth-quarter-year-end-financial-results 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocures-phase-3-pivotal-trial-results-newly-diagnosed-glioblastoma-selected-ascos-clinical-cancer 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/anthem-inc-issues-positive-coverage-decision-optune-newly-diagnosed-glioblastoma 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-present-cowen-and-company-36th-annual-health-care-conference 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-reports-2015-operating-statistics-and-financial-results 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/humana-issues-positive-coverage-decision-optune 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/red-journal-publishes-data-supporting-personalized-treatment-planning-increase-ttfields-efficacy 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-and-leading-cancer-center-enter-preclinical-research-collaboration-study-tumor-treating 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2016-financial-results 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-present-new-preclinical-data-tumor-treating-fields-american-association-cancer-research 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/opportunityanalyzer-glioblastoma-opportunity-analysis-and-forecasts-2024-research-and-markets 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/fda-approves-investigational-device-exemption-rtog-trial-novocures-optune-together-bevacizumab 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocures-optune-now-available-more-360-cancer-treatment-centers-us 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/blue-cross-blue-shield-michigan-issues-positive-coverage-decision-optune 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-delivers-new-informational-resource-glioblastoma-brain-cancer 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-kicks-brain-tumor-awareness-month-new-activities-support-and-inspire-those-affected 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2016-financial-results-and-provides-company-update 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-enters-employment-agreement-william-doyle 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-present-new-preclinical-data-showing-additive-efficacy-tumor-treating-fields-and-pd-1 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-announces-presentation-subgroup-analysis-panova-data-showing-overall-survival-benefit 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-enrolls-last-patient-innovate-trial-testing-tumor-treating-fields-plus-paclitaxel 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-enrolls-last-patient-panova-trial-tumor-treating-fields-plus-chemotherapy-advanced 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-receives-ide-approval-initiate-metis-trial 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-present-jmp-securities-2016-life-sciences-conference 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2016-financial-results 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-announces-75-million-drawdown-under-its-term-loan-agreement-through-pharmakon-advisors 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-receives-fda-approval-second-generation-optune-system 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/nccn-guidelines-recommend-optune-standard-treatment-option-newly-diagnosed-glioblastoma 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2016-financial-results-and-provides-company-update 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-host-research-and-development-day-dec-12-2016 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-present-upcoming-investor-conferences 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-converts-more-500-us-patients-second-generation-optune-within-four-weeks-fda-approval-july 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/international-journal-cancer-publishes-data-showing-tumor-treating-fields-combination-paclitaxel 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/long-term-analysis-all-695-patients-enrolled-novocures-phase-3-pivotal-trial-newly-diagnosed 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/two-institutions-publish-independent-data-novocures-tumor-treating-fields 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocures-executive-chairman-william-doyle-present-tumor-treating-fields-new-york-academy-sciences 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/cns-oncology-publishes-tumor-treating-fields-treatment-planning-and-patient-follow-guidelines 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2016-financial-results 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/correcting-and-replacing-novocure-report-third-quarter-2016-financial-results 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-enrolls-first-patient-phase-3-pivotal-brain-metastases-trial 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-recognizes-national-family-caregivers-month-supporting-gbm-heroes-event 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2016-financial-results-and-provides-company-update 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/united-healthcare-issues-positive-coverage-decision-optune 2025-02-20T12:09:28+01:00 0.5 https://www.novocure.com/novocure-announces-38-presentations-tumor-treating-fields-21st-annual-scientific-meeting-society 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-sponsors-pulitzer-prize-winning-author-dr-siddhartha-mukherjee-keynote-speaker-21st-annual 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-presents-interim-stellar-results-iaslc-suggesting-treatment-tumor-treating-fields-plus 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/long-term-analysis-all-695-patients-enrolled-novocures-phase-3-pivotal-trial-newly-diagnosed-0 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-announces-agenda-research-and-development-day-dec-12-2016 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-presents-phase-2-pilot-innovate-trial-results-suggesting-tumor-treating-fields-plus 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-presents-second-cohort-phase-2-pilot-panova-trial-results-suggesting-tumor-treating-fields 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-participate-35th-annual-jp-morgan-healthcare-conference 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocures-optuner-novottf-100a-approved-japan-treatment-newly-diagnosed-glioblastoma 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-report-fourth-quarter-and-full-year-2016-financial-results 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-announces-preliminary-fourth-quarter-and-full-year-2016-operating-statistics 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocures-optuner-now-available-500-cancer-treatment-centers-us 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-participate-noble-capital-markets-13th-annual-investor-conference 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-participate-bio-2017-ceo-investor-conference 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/first-patient-enrolled-novocures-phase-3-pivotal-lunar-trial-testing-tumor-treating-fields 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2016-financial-results-and-provides-company-update 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-announces-departure-chief-commercial-officer 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-announces-data-presentations-american-association-cancer-research-annual-meeting-2017 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-receives-mhlw-approval-second-generation-optuner-japan 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-present-16th-annual-needham-company-healthcare-conference 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2017-financial-results 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-enrolls-last-patient-stellar-trial-testing-tumor-treating-fields-combination-standard-care 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/combination-tumor-treating-fields-standard-care-therapies-nab-paclitaxel-and-gemcitabine-suggests 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/combination-tumor-treating-fields-paclitaxel-may-improve-survival-patients-recurrent-ovarian-cancer 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/combination-optunetm-standard-care-chemotherapy-temozolomide-provides-landmark-five-year-survival 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/cns-oncology-publishes-data-suggesting-survival-benefit-optunetm-combination-second-line 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocuretm-announces-four-presentations-tumor-treating-fields-american-academy-neurology-annual 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2017-financial-results-and-provides-company-update 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocuretm-announces-data-presentations-world-federation-neuro-oncology-societies-5th-quadrennial 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-present-three-upcoming-investor-conferences-may 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocuretm-announces-opening-two-pilot-trials-evaluate-use-ttfields-pediatric-gliomas 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/combination-optunetm-standard-care-chemotherapy-temozolomide-delayed-decline-several-health-related 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/martin-j-madden-joins-novocure-board-directors 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocuretm-receives-humanitarian-use-device-designation-treatment-pleural-mesothelioma 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-present-jmp-securities-2017-life-sciences-conference 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/health-care-service-corporation-issues-positive-coverage-decision-optune 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/first-patient-enrolled-rtog-trial-optuner-together-bevacizumab-patients-bevacizumab-refractory 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-announces-change-presentation-time-jmp-securities-2017-life-sciences-conference 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-present-three-abstracts-tumor-treating-fields-and-pancreatic-cancer-european-society 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2017-financial-results 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/data-delivery-tumor-treating-fields-be-presented-39th-annual-international-conference-ieee 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocures-optuner-now-available-more-600-cancer-treatment-centers-us 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocuretm-announces-phase-1b-clinical-trial-evaluate-safety-marizomib-and-temozolomide-combination 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2017-financial-results-and-provides-company-update 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-present-2017-wedbush-pacgrow-healthcare-conference 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocuretm-announces-national-reimbursement-optuner-austria 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-present-two-upcoming-investor-conferences-september 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/german-federal-joint-committee-announces-decision-support-clinical-trial-study-optuner-treatment 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-announces-data-presentations-esmo-2017-congress 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/novocure-announces-data-presentations-american-society-radiation-oncologys-2017-annual-meeting 2025-02-20T12:09:58+01:00 0.5 https://www.novocure.com/combination-optuner-temozolomide-demonstrates-unprecedented-five-year-survival-newly-diagnosed 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2017-financial-results 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-data-presentations-iaslc-18th-world-conference-lung-cancer 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2017-financial-results-and-provides-company-update 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-six-clinical-presentations-novocures-phase-3-pivotal-ef-14-trial-data-newly 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-13-preclinical-presentations-highlighting-data-tumor-treating-fields-mechanism 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-10-presentations-simulation-studies-aiming-optimize-treatment-delivery-tumor 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-28-presentations-tumor-treating-fields-externally-led-clinical-research-and 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/patients-who-used-optuner-more-90-percent-time-had-greatest-chance-survival-novocures-ef-14-trial 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-present-two-upcoming-investor-conferences-december 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-receives-reimbursement-approval-optuner-japan-treatment-newly-diagnosed-glioblastoma 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-receives-fda-ide-approval-its-panova-3-phase-3-pivotal-clinical-trial-advanced-pancreatic 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/jama-publishes-final-analysis-ef-14-phase-3-pivotal-trial-optuner-together-temozolomide 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-participate-36th-annual-jp-morgan-healthcare-conference 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-fourth-quarter-and-full-year-2017-operating-statistics-and-preliminary-revenue 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/jama-oncology-publishes-ef-14-pivotal-trial-analysis-showing-optune-plus-temozolomide-improved 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-secures-new-150-million-non-dilutive-term-loan-financing 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-company-update 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-35-presentations-tumor-treating-fields-american-association-cancer-research 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/nccn-guidelines-recommend-optune-combination-temozolomide-category-1-treatment-newly-diagnosed 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2018-financial-results 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/data-tumor-treating-fields-be-presented-american-association-cancer-research-annual-meeting 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-reports-positive-top-line-results-stellar-phase-2-pilot-trial-mesothelioma 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2018-financial-results-and-provides-company-update 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-changes-its-board-directors 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-present-innovate-3-phase-3-pivotal-trial-design-recurrent-ovarian-cancer-american-society 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2018-financial-results 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-appoints-pritesh-shah-chief-commercial-officer 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/scientific-track-dedicated-tumor-treating-fields-40th-international-conference-ieee-engineering 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-13-presentations-american-society-radiation-oncology-2018-annual-meeting 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2018-financial-results-and-provides-company-update 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/gynecologic-oncology-publishes-results-innovate-phase-2-pilot-study-demonstrating-combination-tumor 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-addition-its-board-directors 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-present-two-upcoming-investor-conferences 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-and-us-oncology-research-announce-collaboration-panova-3-trial-patients-advanced 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/tumor-treating-fields-plus-standard-care-chemotherapy-significantly-extends-median-overall-survival 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-and-zai-lab-announce-strategic-collaboration-license-agreement-tumor-treating-fields 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/data-stellar-registration-trial-tumor-treating-fields-mesothelioma-be-presented-iaslc-19th-world 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2018-financial-results 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-55-presentations-european-association-neuro-oncology-meeting-2018 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-medicare-dme-macs-have-accepted-local-coverage-determination-reconsideration 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/pancreatology-publishes-results-panova-phase-2-pilot-trial-advanced-pancreatic-cancer-suggesting 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/higher-delivered-dose-tumor-treating-fields-tumor-bed-associated-improved-overall-survival-newly 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-founder-professor-yoram-palti-and-director-louis-j-lavigne-jr-retire-board-directors 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2018-financial-results-and-provides-company-update 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-and-zai-lab-host-investor-event 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-announces-more-70-presentations-tumor-treating-fields-23rd-annual-meeting-society-neuro 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-and-zai-lab-awarded-deal-year-5th-annual-biocentury-china-healthcare-summit-shanghai-china 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/sub-group-analysis-novocures-ef-14-phase-3-pivotal-trial-newly-diagnosed-glioblastoma-published 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-and-aacr-announce-four-inaugural-research-grants-promote-and-support-innovative-research 2025-02-20T12:12:19+01:00 0.5 https://www.novocure.com/novocure-participate-37th-annual-jp-morgan-healthcare-conference 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-fourth-quarter-and-full-year-2018-operating-statistics-preliminary-net-revenues 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-company-update 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-participate-oppenheimers-29th-annual-healthcare-conference 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocures-chief-science-officer-retires-after-17-years-service 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-48-presentations-and-symposium-session-tumor-treating-fields-american 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-initiates-phase-3-pivotal-trial-recurrent-ovarian-cancer 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2019-financial-results 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/inaugural-aacr-novocure-tumor-treating-fields-research-grant-recipients-announced-aacr-annual 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-publishes-2018-annual-report-featuring-companys-vision-mission-and-values 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-international-journal-radiation-oncology-biology-physics-publishes-data 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2019-financial-results-and-provides-company-update 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/medicare-issues-proposed-local-coverage-determination-provides-coverage-optuner-newly-diagnosed 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/fda-approves-novottf-100ltm-system-combination-chemotherapy-treatment-malignant-pleural 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-participate-jefferies-2019-global-healthcare-conference 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/german-institute-quality-and-efficiency-healthcare-publishes-rapid-report-noting-optunes-survival 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2019-financial-results 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/medicare-releases-final-local-coverage-determination-providing-coverage-optuner-newly-diagnosed 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/cms-establishes-2019-monthly-fee-schedule-amount-optuner 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-10-oral-presentations-and-special-session-tumor-treating-fields-41st 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2019-financial-results-and-provides-company-update 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-participate-three-upcoming-investor-conferences 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/china-national-medical-products-administration-grants-innovative-medical-device-designation-optuner 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-27-presentations-american-society-radiation-oncology-2019-annual-meeting 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2019-financial-results 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/results-stellar-trial-tumor-treating-fields-chemotherapy-malignant-pleural-mesothelioma-published 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2019-financial-results-and-provides-company-update 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-43-presentations-tumor-treating-fields-24th-annual-meeting-society-neuro 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-participate-evercore-isi-2019-healthconx-conference 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-and-aacr-announce-2nd-annual-aacr-novocure-grants-tumor-treating-fields-research-program 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-participate-38th-annual-jp-morgan-healthcare-conference 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/zai-lab-and-novocure-announce-first-patient-enrolled-phase-2-pilot-trial-tumor-treating-fields 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-fourth-quarter-and-full-year-2019-preliminary-net-revenues-and-provides-company 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-national-reimbursement-israel-optuner-combination-temozolomide-treatment-newly 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-company-update 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/preclinical-data-show-tumor-treating-fields-induces-immunogenic-cell-death-resulting-enhanced 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-optune-luatm-brand-name-novottf-100ltm-system 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/german-federal-joint-committee-updates-medical-care-directive-include-tumor-treating-fields 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-provides-business-update-related-covid-19 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-presentation-ef-19-post-approval-registry-trial-data-studying-optune-monotherapy 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2020-financial-results-and-provides-company-update 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/china-nmpa-approves-optuner-treatment-newly-diagnosed-and-recurrent-glioblastoma 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-launch-mylinktm-enable-patient-guided-remote-download-optuner-usage-data 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2020-financial-results 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-enrolls-last-patient-hepanova-trial-testing-tumor-treating-fields-combination-sorafenib 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-over-100-physicians-us-now-certified-prescribe-optune-luatm 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-clinical-trial-collaboration-msd-evaluate-tumor-treating-fields-together 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/first-patient-enrolled-novocures-ef-33-phase-2-pilot-trial-tumor-treating-fields-delivered 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-recipients-2nd-annual-aacr-novocure-grants-tumor-treating-fields-research 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2020-financial-results-and-provides-company-update 2025-02-20T12:12:42+01:00 0.5 https://www.novocure.com/novocure-announces-expansion-its-executive-leadership-team 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-participate-2020-wells-fargo-virtual-healthcare-conference 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-honors-mesothelioma-day-activities-raise-awareness-mesothelioma-and-support-community 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-host-virtual-research-development-day 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2020-financial-results 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-strategic-alliance-nyu-grossman-school-medicine-preclinical-and-clinical 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2020-financial-results-and-provides-company-update 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-proposed-private-placement-500-million-convertible-senior-notes 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-prices-500-million-0-convertible-senior-notes-private-placement 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-closing-575-million-0-convertible-senior-notes-private-placement 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-closing-150-million-revolving-credit-facility-syndicate-relationship-banks 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-agenda-virtual-research-and-development-day 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-receives-ce-mark-novottf-100ltm-system 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-43-presentations-tumor-treating-fields-society-neuro-oncology-2020-virtual 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-participate-evercore-isi-2020-virtual-healthconx-conference 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/first-patient-enrolled-novocures-global-phase-3-trident-trial-optuner-concurrent-radiation-therapy 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-national-reimbursement-switzerland-optuner-combination-temozolomide-treatment 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-participate-39th-annual-jp-morgan-virtual-healthcare-conference 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-fourth-quarter-and-full-year-2020-preliminary-net-revenues-and-provides-company 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-addition-its-board-directors-0 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-company-update 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2021-financial-results 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-26-presentations-american-association-cancer-research-aacr-annual-meeting-2021 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-update-phase-3-pivotal-lunar-trial-tumor-treating-fields-non-small-cell-lung 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-fda-ide-approval-and-steering-committee-keynote-b36-trial-evaluating-tumor 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2021-financial-results-and-provides-company-update 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-fda-approval-ide-supplement-phase-3-pivotal-lunar-trial-tumor-treating-fields 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-clinical-trial-collaboration-gt-medical-technologies-evaluate-tumor-treating 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-initiates-usability-study-flexible-torso-array 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-presents-final-safety-and-efficacy-results-its-phase-2-pilot-hepanova-trial-liver-cancer 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2021-financial-results 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-recipients-3rd-annual-aacr-novocure-grants-tumor-treating-fields-research 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2021-financial-results-and-provides-company-update 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-appoints-bill-burke-chief-human-resources-officer 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-participate-2021-wells-fargo-virtual-healthcare-conference 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/fda-grants-breakthrough-device-designation-novottf-200ttm-system-advanced-liver-cancer 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-clinical-trial-collaboration-roche-evaluate-tumor-treating-fields-part-novel 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-and-zai-lab-announce-last-patient-enrolled-phase-2-pilot-trial-tumor-treating-fields-plus 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2021-financial-results 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-15-presentations-american-society-radiation-oncology-2021-annual-meeting 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-last-patient-enrolled-phase-3-pivotal-innovate-3-trial-tumor-treating-fields 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2021-financial-results-and-provides-company-update 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-31-presentations-tumor-treating-fields-society-neuro-oncology-2021-annual 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/2-top-phase-2-trial-reports-positive-top-line-results-newly-diagnosed-glioblastoma 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-last-patient-enrolled-phase-3-pivotal-lunar-trial-tumor-treating-fields-non 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-participate-two-upcoming-investor-conferences 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-4th-annual-aacr-novocure-grants-tumor-treating-fields-research-program 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-signs-agreement-acquire-and-construct-building-downtown-portsmouth-new-hampshire 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-participate-40th-annual-jp-morgan-healthcare-conference 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-announces-preliminary-full-year-and-fourth-quarter-2021-net-revenues-and-provides-company 2025-02-20T12:13:06+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-company-update 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/new-data-finds-tumor-treating-fields-initiates-downstream-anti-tumor-response 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocures-general-counsel-resigns-after-10-years-service 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-founder-yoram-palti-wins-2022-israel-prize-entrepreneurship-and-technological-innovation 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-favorable-recommendation-continue-phase-3-pivotal-innovate-3-study-tumor 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/updated-2-top-data-suggest-improvements-progression-free-survival-overall-survival-compared-matched 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2022-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-19-presentations-american-association-cancer-research-aacr-annual-meeting-2022 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-hosts-ceremonial-groundbreaking-new-hampshire-governor-chris-sununu 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2022-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-clinical-collaboration-msd-registrational-intent-study-evaluate-tumor-treating 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-and-zai-lab-announce-ef-31-phase-2-pilot-study-evaluating-tumor-treating-fields-together 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-enrolls-first-patient-keynote-b36-pilot-study-tumor-treating-fields-together-keytrudar 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2022-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-recipients-4th-annual-aacr-novocure-grants-tumor-treating-fields-research 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2022-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-hosts-us-sen-maggie-hassan-companys-portsmouth-facility 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-participate-upcoming-investor-conferences 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-creation-us-cns-cancers-franchise-intended-renew-focus-growth-glioblastoma 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2022-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-launches-campaign-drive-awareness-and-understanding-tumor-treating-fields-therapy 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-review-article-anti-cancer-mechanisms-action-tumor-treating-fields-published 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-11-presentations-tumor-treating-fields-multiple-solid-tumor-types-american 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2022-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-secures-ce-mark-new-array 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-opens-office-montreal-expand-and-support-growing-business-canada 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-25-abstracts-tumor-treating-fields-therapy-society-neuro-oncology-2022-annual 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-participate-34th-annual-piper-sandler-healthcare-conference 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocures-optuner-approved-canada-treatment-newly-diagnosed-and-recurrent-glioblastoma 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-participate-41st-annual-jp-morgan-healthcare-conference 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-pivotal-lunar-study-non-small-cell-lung-cancer-met-primary-overall-survival 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-preliminary-full-year-and-fourth-quarter-2022-net-revenues-and-provides-company 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-organizational-changes-prepare-future-growth 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-last-patient-enrolled-pivotal-panova-3-study-tumor-treating-fields-pancreatic 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/allyson-j-ocean-md-joins-novocure-board-directors 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-company-update 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-last-patient-enrolled-pivotal-metis-study-tumor-treating-fields-brain-metastases 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-reimbursement-optuner-treatment-newly-diagnosed-glioblastoma-france 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-5th-annual-aacr-novocure-grants-tumor-treating-fields-research-program 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/kristin-stafford-joins-novocure-board-directors 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2023-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-27-presentations-including-real-world-evidence-and-preclinical-research-american 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-presentation-results-lunar-phase-3-clinical-trial-non-small-cell-lung-cancer 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2023-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-pledges-3-million-conquer-cancerr-asco-foundation-support-cancer-research-and-education 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/lunar-phase-3-clinical-trial-demonstrates-statistically-significant-and-clinically-meaningful 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2023-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-announces-favorable-independent-data-monitoring-committee-recommendation-continue-phase-3 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2023-financial-results 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-participate-upcoming-investor-conferences-0 2025-02-20T12:13:43+01:00 0.5 https://www.novocure.com/novocure-provides-update-phase-3-engot-ov50-gog-3029-innovate-3-trial-evaluating-tumor-treating 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-lancet-oncology-publishes-primary-data-phase-3-lunar-clinical-trial-patients 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-highlights-use-tumor-treating-fields-therapy-treatment-non-small-cell-lung-cancer-2023 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-presence-american-society-radiation-oncology-astro-2023-annual-meeting 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2023-financial-results 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-and-stanford-school-medicine-establish-tumor-treating-fields-research-program 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-presence-european-society-medical-oncology-esmo-congress-2023 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2023-financial-results 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-participate-35th-annual-piper-sandler-healthcare-conference 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-portfolio-prioritization-and-strategic-restructuring-plan-focused-near-term 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-participate-42nd-annual-jp-morgan-healthcare-conference 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-appoints-dr-nicolas-leupin-chief-medical-officer 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-preliminary-full-year-and-fourth-quarter-2023-net-revenues-and-provides-company 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-last-patient-enrolled-phase-3-trident-trial-newly-diagnosed-glioblastoma 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-fda-acceptance-pma-application-ttfields-therapy-non-small-cell-lung-cancer 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-company-update 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/innovate-3-late-breaking-abstract-selected-best-oral-presentation-esgo 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/metis-phase-3-clinical-trial-met-primary-endpoint-demonstrating-statistically-significant-extension 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2024-financial-results 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-20-presentations-tumor-treating-fields-highlighting-preclinical-effects 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/results-novocures-metis-phase-3-clinical-trial-patients-brain-metastasis-non-small-cell-lung-cancer 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2024-financial-results 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-secures-new-400-million-multi-tranche-non-dilutive-debt-financing-pharmakon 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/tiger-study-reports-new-ttfields-therapy-survival-results-newly-diagnosed-glioblastoma-patients 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/metis-phase-3-clinical-trial-met-primary-endpoint-significantly-delaying-time-intracranial 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2024-financial-results 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2024-financial-results 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-highlights-ttfields-therapy-treatment-non-small-cell-lung-cancer-2024-world-conference 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-participate-2024-wells-fargo-healthcare-conference 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-announces-planned-ceo-transition 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-present-real-world-data-esmo-2024-demonstrating-improved-survival-outcomes-newly-diagnosed 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2024-financial-results 2025-02-20T12:15:14+01:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2024-financial-results 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-appoints-christoph-brackmann-chief-financial-officer 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/fda-approves-novocures-innovative-hfe-transducer-arrays-use-optune-gior-glioblastoma 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-data-2024-sno-annual-meeting-highlights-product-innovation-and-real-world-evidence-tumor 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-participate-upcoming-investor-conferences-1 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-positive-topline-results-phase-3-panova-3-clinical-trial-tumor-treating-fields 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-participate-43rd-annual-jp-morgan-healthcare-conference 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-preliminary-full-year-and-fourth-quarter-2024-performance-and-provides-company 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/data-phase-iii-trial-recurrent-glioblastoma-tumors-published-pnas 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/results-pilot-study-breast-cancer-presented-aacr 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/results-phase-iii-trial-newly-diagnosed-glioblastoma-presented-sno 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/financing-round-completed-new-investors-pfizer-johnson-johnson-development-corporation-and-index 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/results-phase-iii-trial-recurrent-glioblastoma-tumors-presented-asco 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/results-phase-ii-trial-advanced-nsclc-presented-esmo 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/fda-neurological-devices-advisory-committee 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/fda-approves-novottf-100a-system-treatment-recurrent-gbm 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-announces-presentations-tumor-treating-fields-therapy-including-new-clinical-data-and-real 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/fda-approves-novocures-optune-luar-treatment-metastatic-non-small-cell-lung-cancer 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-inaugurates-new-global-headquarters-canton-zug-switzerland 2025-02-20T12:07:57+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-company-update-1 2025-04-08T13:15:02+02:00 0.5 https://www.novocure.com/novocure-participate-leerink-partners-2025-global-healthcare-conference-1 2025-04-08T13:15:02+02:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2025-financial-results-1 2025-04-08T13:15:02+02:00 0.5 https://www.novocure.com/novocures-optune-luar-receives-ce-mark-approval-treatment-metastatic-non-small-cell-lung-cancer 2025-04-22T13:10:08+02:00 0.5 https://www.novocure.com/novocure-present-results-phase-3-panova-3-clinical-trial-its-tumor-treating-fields-ttfields-therapy 2025-04-23T16:22:02+02:00 0.5 https://www.novocure.com/novocure-reports-first-quarter-2025-financial-results 2025-04-24T13:02:10+02:00 0.5 https://www.novocure.com/novocure-announces-upcoming-investor-events 2025-05-27T13:15:02+02:00 0.5 https://www.novocure.com/results-phase-3-panova-3-trial-novocures-tumor-treating-fields-ttfields-therapy-pancreatic-cancer 2025-05-31T14:01:03+02:00 0.5 https://www.novocure.com/novocure-report-second-quarter-2025-financial-results 2025-06-30T13:01:09+02:00 0.5 https://www.novocure.com/novocure-present-final-secondary-endpoint-data-phase-3-panova-3-trial-tumor-treating-fields 2025-07-01T13:01:16+02:00 0.5 https://www.novocure.com/novocure-reports-second-quarter-2025-financial-results 2025-07-24T13:01:12+02:00 0.5 https://www.novocure.com/novocure-submits-premarket-approval-application-fda-tumor-treating-fields-therapy-locally-advanced 2025-08-20T13:15:28+02:00 0.5 https://www.novocure.com/novocure-announces-coverage-tumor-treating-fields-ttfields-therapy-patients-newly-diagnosed 2025-08-25T13:15:20+02:00 0.5 https://www.novocure.com/novocure-announces-upcoming-investor-events-3 2025-08-28T13:15:21+02:00 0.5 https://www.novocure.com/novocures-optune-luar-receives-approval-japan-treatment-unresectable-advancedrecurrent-non-small 2025-09-15T13:15:17+02:00 0.5 https://www.novocure.com/novocure-present-final-results-pivotal-phase-3-metis-trial-its-tumor-treating-fields-ttfields 2025-09-29T23:15:21+02:00 0.5 https://www.novocure.com/novocure-report-third-quarter-2025-financial-results 2025-10-01T13:01:24+02:00 0.5 https://www.novocure.com/novocure-present-new-research-tumor-treating-fields-ttfields-therapy-european-association-neuro 2025-10-15T13:01:23+02:00 0.5 https://www.novocure.com/novocure-reports-third-quarter-2025-financial-results 2025-10-30T12:01:23+01:00 0.5 https://www.novocure.com/novocure-participate-2025-jefferies-global-healthcare-conference 2025-11-12T13:01:22+01:00 0.5 https://www.novocure.com/novocure-participate-37th-annual-piper-sandler-healthcare-conference 2025-11-26T13:01:22+01:00 0.5 https://www.novocure.com/novocure-appoints-company-president-frank-leonard-chief-executive-officer 2025-12-01T13:01:20+01:00 0.5 https://www.novocure.com/novocure-present-44th-annual-jp-morgan-healthcare-conference 2025-12-22T13:01:16+01:00 0.5 https://www.novocure.com/novocure-announces-preliminary-full-year-and-fourth-quarter-2025-performance-and-provides-company 2026-01-12T13:01:24+01:00 0.5 https://www.novocure.com/us-fda-approves-novocures-optune-paxr-treatment-locally-advanced-pancreatic-cancer 2026-02-11T23:54:21+01:00 0.5 https://www.novocure.com/tumor-treating-fields-ttfields-therapy-be-covered-patients-newly-diagnosed-glioblastoma-through 2026-02-24T13:01:17+01:00 0.5 https://www.novocure.com/novocure-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-company-update 2026-02-26T13:01:21+01:00 0.5 https://www.novocure.com/novocure-participate-2026-leerink-global-healthcare-conference 2026-02-27T22:31:22+01:00 0.5 https://www.novocure.com/novocure-announces-optune-luar-receives-reimbursement-approval-japan-treatment-non-small-cell-lung 2026-03-02T13:01:26+01:00 0.5 https://www.novocure.com/novocure-announces-positive-topline-results-phase-2-panova-4-clinical-trial-tumor-treating-fields 2026-03-26T12:01:24+01:00 0.5 https://www.novocure.com/novocure-report-first-quarter-2026-financial-results 2026-04-01T13:01:25+02:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/christoph-brackmann 2025-02-21T11:01:07+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/investing-in-true-innovation 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/our-people-cristina-messina 2025-02-21T12:51:25+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/our-people-dardan-osmani 2026-02-19T14:34:52+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/our-people-caleigh-olds 2026-02-19T14:26:56+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/our-people-juergen-schaller 2026-02-19T14:17:11+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/lynn-oxenberg 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/justin-charrette 2026-02-18T17:42:42+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/why-innovation-takes-courage 2026-02-19T13:42:15+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/supporting-investigators-in-ttfields-clinical-trials 2026-02-19T13:34:53+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/reinventing-our-first-contact-with-patients 2026-02-19T13:27:27+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/supporting-patients-in-israel 2026-02-19T12:53:04+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/jana-meyer-zu-drewer-making-our-therapy-accessible-to-patients-motivates-me 2026-02-19T12:28:58+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/the-courage-of-our-patients-inspired-me-to-keep-going 2026-02-19T11:44:16+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/shelly-zaugg 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/kyle-garcia 2026-02-18T17:34:23+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/lea-pachur-from-hospitality-to-medtech 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/investor-relations/investor-relations/events 2025-12-23T13:39:12+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/offering-a-hand-and-lending-an-ear-to-patients 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/features/ignace-vergote-novocure-clinical-trial-investigator 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/features/standing-with-the-brain-tumor-community 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/the-foundation-of-trust 2026-02-19T11:25:47+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/making-a-difference-as-a-business-analyst 2026-02-19T11:19:26+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/d-j-stewart 2026-02-18T17:22:05+01:00 0.5 https://www.novocure.com/sitemap 2025-02-21T11:50:34+01:00 0.5 https://www.novocure.com/california-consumer-privacy-notice 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/novocure-website-privacy-notice 2026-01-20T12:58:55+01:00 0.5 https://www.novocure.com/privacy-policy 2025-06-30T11:00:59+02:00 0.5 https://www.novocure.com/novocure-vulnerability-disclosure-process 2025-12-23T13:06:18+01:00 0.5 https://www.novocure.com/terms-and-conditions 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/corporate-compliance 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/features/novocure-joins-new-hampshire-life-sciences 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/features/lighting-the-world-blue 2026-02-19T17:06:22+01:00 0.5 https://www.novocure.com/patient-forward/stories/features/novocure-pledges-250k-to-families-first-health-and-support-center 2025-02-20T12:17:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/features/a-qa-with-our-founder 2026-02-19T16:56:52+01:00 0.5 https://www.novocure.com/contact-us 2026-01-13T11:32:54+01:00 0.5 https://www.novocure.com/patient-forward/features 2025-02-21T12:28:59+01:00 0.5 https://www.novocure.com/patient-forward/patient-forward 2026-02-23T11:44:28+01:00 0.5 https://www.novocure.com/news-and-media/news-and-media 2026-01-26T14:55:58+01:00 0.5 https://www.novocure.com/careers/our-global-community 2026-01-13T11:33:51+01:00 0.5 https://www.novocure.com/patient-forward/our-culture 2026-02-19T15:53:52+01:00 0.5 https://www.novocure.com/careers/careers 2026-02-18T14:50:13+01:00 0.5 https://www.novocure.com/investor-relations/corporate-governance 2026-01-09T17:41:58+01:00 0.5 https://www.novocure.com/investor-relations/investor-relations/annual-reports 2025-04-21T15:01:39+02:00 0.5 https://www.novocure.com/investor-relations/sec-filing 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/investor-relations/stock-information 2025-02-21T15:21:26+01:00 0.5 https://www.novocure.com/investor-relations/investor-relations/home 2026-02-25T13:19:30+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/jeryl-hilleman 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/michael-puri 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/moshe-giladi-ph-d 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/uri-weinberg 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/nicolas-leupin 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/frank-leonard 2025-12-01T13:00:51+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/mukund-paravasthu 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/barak-ben-arye 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/yoram-palti-m-d-ph-d 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/asaf-danziger 2025-02-21T11:04:12+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/william-f-doyle 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/node/567 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/patient-forward/patient-experience 2025-11-19T17:47:37+01:00 0.5 https://www.novocure.com/press-releases 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/linda-long 2026-02-19T16:15:03+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/janice-armbrust 2026-02-19T16:10:16+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/william-a-vernon 2026-02-26T13:39:37+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/kristin-stafford-cpa 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/timothy-j-scannell 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/allyson-j-ocean-m-d 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/martin-j-madden 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/kinyip-gabriel-leung 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/about-us/our-leadership/our-leader/david-t-hung 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/patient-forward/stories/features/patient-advocacy-groups 2026-02-19T16:56:32+01:00 0.5 https://www.novocure.com/patient-forward/stories/features/extra-in-the-ordinary 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/practicing-empathy 2026-02-19T11:11:46+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/enabling-smooth-starts 2026-02-19T11:02:49+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/enhancing-awareness-scientific-understanding-of-ttfields-therapy 2025-02-20T12:18:29+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/karin-gottwald-we-live-our-patient-forward-mission 2026-02-19T10:45:44+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/alice-chen-behind-the-scenes-of-our-clinical-trials 2026-02-19T16:02:47+01:00 0.5 https://www.novocure.com/patient-forward/stories/our-culture/unafraid-to-innovate 2026-02-23T11:35:30+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/jovan-knutson 2026-02-18T17:13:30+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/mike-hugo 2026-02-18T17:05:50+01:00 0.5 https://www.novocure.com/our-pipeline 2026-01-13T11:23:38+01:00 0.5 https://www.novocure.com/about-us/external-funding 2025-02-21T12:04:31+01:00 0.5 https://www.novocure.com/about-us/advocacy 2026-02-18T13:01:59+01:00 0.5 https://www.novocure.com/about-us/our-leadership 2026-02-26T13:39:38+01:00 0.5 https://www.novocure.com/about-us/our-story/our-history 2026-02-18T12:14:28+01:00 0.5 https://www.novocure.com/about-us/our-story/our-story 2025-10-30T12:59:40+01:00 0.5 https://www.novocure.com/home 2026-02-25T13:28:26+01:00 0.5 https://www.novocure.com/patient-forward/stories/patient-experience/bruce-stahlman 2025-02-20T14:32:20+01:00 0.5 https://www.novocure.com/events/novocure-jefferies-global-healthcare-conference 2025-11-26T13:44:23+01:00 0.5 https://www.novocure.com/purchase-order-terms-and-conditions 2025-08-28T16:53:36+02:00 0.5 https://www.novocure.com/events/novocure-q3-2025-earnings-conference-call 2025-10-01T15:54:36+02:00 0.5 https://www.novocure.com/events/piper-healthcare-conference 2025-11-26T13:44:44+01:00 0.5 https://www.novocure.com/ttfields 2025-12-01T11:29:29+01:00 0.5 https://www.novocure.com/events/novocure-q4-2025-earnings-conference-call 2026-01-28T19:53:40+01:00 0.5 https://www.novocure.com/externals/mynovocure/maintenance 2026-02-05T14:52:10+01:00 0.5 https://www.novocure.com/events/leerink-global-healthcare-conference 2026-03-05T17:15:52+01:00 0.5 https://www.novocure.com/events/q1-2026-earnings 2026-04-01T13:02:01+02:00 0.5